A $50 million Series A gives RealSense its own capital base after 14 years within Intel. The newly independent camera company is betting that rising demand for machine perception warrants a business built around it. Its next priorities connect that bet to practical deployment: safer robot
The search for a virtual biopsy alternative has led to the development of AI models that analyze gray-level co-occurrence and run-length matrices within standard CT images. This methodology is currently revolutionizing how oncologists approach bladder cancer, a disease that remains one of the most
Recent research indicates that individuals diagnosed with cancer within the last year are twice as likely to seek supplementary information through generative AI tools. This surge in digital inquiry marks a departure from traditional medical reliance, suggesting that the shock of a new diagnosis
High-performance AI models often suffer from poor generalizability when they are validated on only a single, narrow dataset from one institution. This limitation poses a significant hurdle in neuro-oncology, where the stakes for accurate diagnosis are exceptionally high. In the United States, the
The contemporary corporate landscape has reached a decisive inflection point where the superficial charm of generative AI pilots has officially given way to the rigorous demands of enterprise-grade performance. As organizations move beyond the initial excitement of 2024 and 2025, the focus has
The rapid proliferation of autonomous agentic workflows within the modern enterprise landscape has created a significant identity management vacuum that threatens to undermine years of progress in digital security. As organizations aggressively deploy these AI entities to automate complex business
